Effect of Sago-based Product on Glycaemic and Lipid Control in Diabetes (SAGODM)
Effect of 12 Weeks Consumption of Sago Based Products in a Malaysian Diet on Glycaemic and Lipid Control in Diabetic Patients: a Double-Blind, Randomised, Parallel Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Teck Long King
- Phone Number: 60168911615
- Email: kingtl@crc.moh.gov.my
Study Locations
-
-
Sarawak
-
Kuching, Sarawak, Malaysia, 93586
- Sarawak General Hospital
-
Kuching, Sarawak, Malaysia, 93250
- Klinik Kesihatan Batu Kawah
-
Kuching, Sarawak, Malaysia, 93400
- Klinik Kesihatan Jalan Masjid
-
Kuching, Sarawak, Malaysia, 93400
- Klinik Kesihatan Tanah Puteh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 - 70 years old
- Individual diagnosed with type 2 diabetes for at least three months
- Not on any antidiabetic medications or on lifestyle modification or taking a stable dose of oral hypoglycaemic agents, with no change of dose and regime for the past eight weeks
- Has HbA1C values of 6.5 - 8.5% within 28 days before commencing the study
- Able to complete the clinical study, and
- Able to provide written informed consent
Exclusion Criteria:
- History of allergy to sago starch or corn starch
- History of allergy to any other ingredients in the study foods
- Clinically significant, active and acute cardiovascular disease
- Clinically significant, stage 4 - 5 (estimated glomerular filtration rate <30mL/min/1.73m2), chronic kidney failure
- Clinically significant chronic liver disease or infection
- Any malignancies
- Regular use of hormone medications, anti-inflammatory medication, steroids, or other medications that might interfere with outcome measure
- On a prescribed therapeutic diet
- Taking part in weight loss programme
- Clinically significant abnormal laboratory investigations
- Other medical conditions or reasons, in the opinion of the Investigator or Research Physician, that make one unsuitable to join the study
- Concurrent participation in other clinical studies involving intervention or treatment towards obesity, diabetes or impaired glucose
- Pregnant or lactating mothers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention Arm
Subjects who are randomised to Intervention Arm will be taking a drink containing 25g of Sarawak sago starch in 200mL of plain water.
The subjects will take the drink twice daily i.e., within 30 minutes before lunch and dinner.
On top of that, they will be counselled on diet recommendations for diabetes by a study dietitian at Visit 1 or baseline.
|
Sarawak sago starch drink will be provided by CRAUN throughout the study.
The starch drink will be supplied in sealed aluminium sachets.
Each sachet contains 25g of study starch with cocoa flavouring.
|
|
Placebo Comparator: Control Arm
Subjects who are randomised to Control Arm will be taking a drink containing 25g of corn starch in 200mL of water.
The subjects will take the starch suspension twice daily i.e., within 30 minutes before lunch and dinner.
On top of that, they will be counselled on diet recommendation for diabetes by a study dietitian at Visit 1 or baseline.
|
Corn starch drink will be provided by CRAUN throughout the study.
The starch drink will be supplied in sealed aluminium sachets.
Each sachet contains 25g of study starch with cocoa flavouring.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of HbA1C value
Time Frame: 12 weeks
|
The change of HbA1C value at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of fasting blood glucose (FBG) level
Time Frame: 12 weeks
|
The change of FBG level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) value
Time Frame: 12 weeks
|
The change of HOMA of insulin resistant value at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of triglycerides level
Time Frame: 12 weeks
|
The change of triglycerides level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of total cholesterol level
Time Frame: 12 weeks
|
The change of total cholesterol level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of low density lipoprotein cholesterol (LDL-C) level
Time Frame: 12 weeks
|
The change of LDL-C level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of high density lipoprotein cholesterol (HDL-C) level
Time Frame: 12 weeks
|
The change of HDL-C level at 12 weeks of intervention from baseline
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of inflammatory marker levels: high-sensitive c-reactive protein (hs-CRP) level
Time Frame: 12 weeks
|
The change of hs-CRP level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of inflammatory marker levels: interleukin 6 (IL-6) level
Time Frame: 12 weeks
|
The change of IL-6 level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of inflammatory marker levels: blood ferritin level
Time Frame: 12 weeks
|
The change of blood ferritin level at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of total daily calorie intake
Time Frame: 12 weeks
|
The change of total daily calorie intake at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of body weight/body mass index (BMI)
Time Frame: 12 weeks
|
The change of BMI at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of body fat and visceral fat percentages
Time Frame: 12 weeks
|
The change of body fat and visceral fat percentages at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of waist-hip ratio from baseline
Time Frame: 12 weeks
|
The change of waist-hip ratio at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of blood pressure from baseline
Time Frame: 12 weeks
|
The change of systolic and diastolic blood pressure at 12 weeks of intervention from baseline
|
12 weeks
|
|
Change of heart rate from baseline
Time Frame: 12 weeks
|
The change of heart rate at 12 weeks of intervention from baseline
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Xun Ting Tiong, Clinical Research Centre Sarawak General Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRC003-SAGODM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.